Precision Immuno-Oncology for advanced Non-small cell lung cancer patients with PD-1 ICI Resistance (PIONeeR clinical study)

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515532-72-00

Acronym

PIONeeR TRIAL

Enrollment

130

Registered

2024-09-25

Start date

2019-10-08

Completion date

2025-08-11

Last updated

2025-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non small cell lung cancer

Brief summary

the determination of 12-week Disease Control Rate (DCR) assessed in each arm of treatment

Detailed description

the proportion of patients with complete response (CR) or partial response (PR) as best overall response over the treatment period., The Progression-free survival

Interventions

DRUGAZD6738

DRUGSavolitinib

DRUGCeralasertib

DRUGDURVALUMAB

DRUGMonalizumab

DRUGDOCETAXEL

DRUGOleclumab

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
the determination of 12-week Disease Control Rate (DCR) assessed in each arm of treatment	—

Secondary

Measure	Time frame
the proportion of patients with complete response (CR) or partial response (PR) as best overall response over the treatment period., The Progression-free survival	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026